Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)Effect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3040)The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-8Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr e13059)CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2525)Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2524)Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-804The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-220
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution